FemTherapeutics

FemTherapeutics Inc. is a healthcare startup founded in 2019 and based in Canada. The company's slogan, "Personalizing Therapeutics for Pelvic Health," encapsulates its mission to provide patient-specific intra-vaginal devices for common pelvic health conditions. Leveraging artificial intelligence and 3D printing, FemTherapeutics aims to revolutionize gynecological care with its innovative approach. The company's flagship product is a custom pessary designed to manage Pelvic Organ Prolapse and Stress Urinary Incontinence, conditions that impact 50% of women during their lifetime. This innovation addresses a significant unmet need in women's health. Furthermore, FemTherapeutics is positioning itself for future growth by planning expansion into other pelvic health categories, including menstruation and sexual wellness, labor and delivery, and oncology. In March 2023, FemTherapeutics received a significant boost with a $2.50M Seed Round investment from prominent investors such as 2048 Ventures, Investissement Québec, SheBoot, and The 51 Ventures. This investment not only signifies confidence in FemTherapeutics' vision but also provides the necessary capital to fuel the company's research, development, and market expansion efforts. With this latest injection of funds, FemTherapeutics is well-positioned to continue its pioneering work in personalized therapeutics for pelvic health.